Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
30 results
D1.189 - Does Allergen Immunotherapy Add Clinically Meaningful Benefit in Paediatric Asthma and Allergic Rhinitis? A 36-Month Real-World Comparison
D1.192 - Combined Polymerized Pollen and Animal Dander Immunotherapy Improves Rhinoconjunctivitis and Asthma in Polysensitized Patients: Real-World Evidence
D1.194 - Real-World Effectiveness of Polymerized Dog Allergen Immunotherapy in Allergic Rhinoconjunctivitis and Asthma
D1.195 - Fc-Engagers as a targeted approach for antigen-specific immune inhibition in HDM allergy
D1.197 - Safety and efficacy of a modified one-day ultra-rush protocol for the induction of Hymenoptera venom immunotherapy in patients with anaphylaxis in Switzerland
D1.186 - Three years treatment with HDM injection allergen immunotherapy, omalizumab, or combination therapy in allergic asthma
D1.187 - A Novel Volume-Reduced Desensitization Protocol for Pembrolizumab Hypersensitivity in Advanced Lung Cancer
D1.188 - Adverse Reactions During Honey Bee Venom Immunotherapy as an Indicator of Underlying Clonal Mast Cell Disease Independent of Baseline Serum Tryptase: A Case Report
D1.191 - Respiratory bacterial lysate (OM-85)-loaded dissolving microneedle array patch modulates HDM-induced allergic airway inflammation and airway hyperresponsiveness in a murine asthma model
D1.198 - Efficacy of Cat Allergen Immunotherapy: A Multicenter Prospective Study
D1.199 - Severe vernal keratoconjunctivitis with allergic rhinitis treated with house dust mite (HDM) sublingual immunotherapy (SLIT)
- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells
- D1.529 - Evaluating the Disease-Modifying Potential of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis: An Update on the Pivotal HARBOR Study
- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib
- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series
- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis
D3.121 - Evaluation of small airway dysfunction in severe asthma treated with anti-IgE and anti-eosinophilic therapies: A prospective comparative study
D3.109 - Clinical Characteristics of Asthma Patients with Fungal Sensitization: A Retrospective Cross-Sectional Study
D3.110 - Patterns of Opioid or Neuromodulator Use in Chronic Cough Patients with Newly Diagnosed Asthma
D3.111 - The Impact of War on the Course of Asthma
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download